Cycle Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CYCLE
CYCLE has thirteen approved drugs.
There are four US patents protecting CYCLE drugs.
Summary for Cycle
| US Patents: | 4 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Cycle
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-002 | Dec 9, 2022 | RX | Yes | Yes | 10,555,902 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | 9,925,138 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cycle | CIMETIDINE | cimetidine | TABLET;ORAL | 074361-001 | Dec 23, 1994 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Cycle | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 085331-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Cycle | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070354-001 | Jun 18, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cycle Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 107530301 | ⤷ Start Trial |
| Hungary | E050881 | ⤷ Start Trial |
| Australia | 2016209466 | ⤷ Start Trial |
| United Kingdom | 201400117 | ⤷ Start Trial |
| Australia | 2016209466 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cycle Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613288 | SPC/GB11/045 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
| 1613288 | PA2011010 | Lithuania | ⤷ Start Trial | PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317 |
| 1539166 | 2013/055 | Ireland | ⤷ Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 0591275 | 05C0024 | France | ⤷ Start Trial | PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221 |
| 0627406 | SPC/GB11/026 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
